Copper peptides: why GHK-Cu is not just a skincare trend

Of every peptide on the longevity menu, GHK-Cu is the only one sold under a name that names its metal cofactor. The copper does the work. Without it, the tripeptide is mostly a small, biologically modest fragment. With it, you have a different molecule with a fifty-year evidence trail and a regulatory file that is currently moving in two opposite directions at once.

Here is what a copper peptide actually is, what the published human evidence supports, and where the injectable form sits in the FDA’s second-wave review.

What makes a copper peptide a copper peptide

The compound is three amino acids — glycine, histidine, lysine — bound around a single copper(II) ion. The technical word is a chelate: the three side chains grab the copper, hold it in a specific geometry, and present it to the cell.

That matters because copper, on its own, is a problem. Free copper ions in tissue catalyse oxidative damage and have to be tightly controlled. The body shuttles copper around inside dedicated chaperone proteins and never lets meaningful concentrations float free. A copper peptide is essentially a delivery vehicle — copper packaged in a form the body’s machinery can read and place where it needs to go.

The biology this packaging unlocks is the part the longevity literature builds on. Copper is a cofactor for enzymes the body uses to build connective tissue: lysyl oxidase (which crosslinks collagen), superoxide dismutase (an antioxidant enzyme), and the cytochrome-c-oxidase complex (which the mitochondria use to run the electron transport chain). A copper peptide presented to a cell can engage those systems in ways free copper cannot, and free GHK without copper cannot.

That is the chemistry behind the marketing. The biology of where it actually leads is more contested.

How the field discovered the copper

The original discovery moment is sometimes told as a 1973 culture-flask observation by Loren Pickart — human plasma added to senescent liver cells made them younger. Pickart isolated the active fraction and found a tripeptide. For years the field thought GHK was the active entity.

The 1979 Pickart, Thaler and Millard paper in the Journal of Chromatography is the methodological turn that revised that. The group had been losing yield during plasma purification — the tripeptide kept disappearing through the chelating resins meant to remove metals. They ran it again with the metal-binding step removed. Recovery jumped roughly eight-fold. The conclusion was that GHK had been travelling with copper the whole time, and the copper-bound complex — not free GHK — was the bioactive form.

That is why the molecule is sold as GHK-Cu and not as GHK. Topical formulations using “GHK” without copper rely on the peptide coordinating with copper already in the skin; that is a different assumption than injecting the pre-formed complex.

What the modern mechanism work actually shows

The current case for GHK-Cu as a regenerative agent rests on roughly two decades of cell-culture and animal-model work, dominated by Pickart’s group and reviewed in two long surveys.

Pickart, Vasquez-Soltero and Margolina (2015, BioMed Research International) gathered the multi-pathway story: in cultured cells, GHK-Cu upregulates collagen, dermatan sulphate, chondroitin sulphate, and decorin synthesis. It modulates the metalloproteinases that remodel the extracellular matrix. It attracts immune and endothelial cells to wound sites in animal models, accelerating closure. The review also surfaces the population-level fact the marketing leans on: plasma GHK declines from roughly 200 nanograms per millilitre at age 20 to about 80 nanograms per millilitre by age 60.

Pickart and Margolina (2018, Int J Mol Sci) extended that into gene-expression data: GHK-Cu correlates with the activation of regenerative programmes — blood-vessel and nerve outgrowth, collagen-elastin-glycosaminoglycan synthesis, fibroblast support, suppression of ageing-associated NF-kappaB inflammation — that read like a list of everything a sceptical reviewer would ask a longevity intervention to plausibly engage.

That mechanism volume is real. It is also a single research group’s output across most of those years; independent Western replication is sparse. And cell-culture and animal evidence is not the same evidence category as a human trial measuring an outcome anyone cares about.

The one human randomised trial

That trial happened in 2006. Miller and colleagues, Arch Facial Plast Surg randomised thirteen patients undergoing CO2 laser facial resurfacing to a GHK-Cu skincare regimen or the identical regimen without the peptide during recovery. Blinded evaluators scored erythema, wrinkles, and overall skin quality at twelve weeks. Computer analysis cross-checked the visible-skin endpoints.

The objective endpoints came back null. Erythema, wrinkles, skin quality — no significant difference between arms. Patient-reported satisfaction was the only endpoint that reached significance (P=0.04), which is the kind of result the satisfaction literature is consistently good at producing whether or not the treatment did anything.

Twenty years on, this remains the single published randomised human trial of GHK-Cu skincare. Mortazavi and colleagues (2025, Bioimpacts) write the open question plainly: despite widespread cosmetic use, the published information on skin permeability, effectiveness, and physicochemical properties of GHK-Cu and palmitoyl-GHK is insufficient to confirm site-of-action efficacy. That is the academic 2025 position on the cosmetic application. The systemic-anti-ageing application has no published controlled human trial at all.

The two routes are moving in opposite directions

The regulatory file is where the article’s title earns itself. GHK-Cu does not appear on the FDA Pharmacy Compounding Advisory Committee’s July 23-24, 2026 docket — that wave covers BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, and Epitalon. GHK-Cu is in the second wave, scheduled before the end of February 2027, and both routes of administration are on it. The injectable route and the non-injectable (topical) route moved in opposite directions to get there.

The injectable form came off the Section 503A Category 2 list — the FDA’s banned-for-compounding category, the list a substance lands on when safety concerns are deemed significant. The injectable was banned. Now its categorical ban is lifted, pending the Wave 2 review. That is regulatory movement toward, not away from, allowing the compound to be prescribed.

The non-injectable form moved the other way. It came off the Section 503A Category 1 list — the under-evaluation category, the list a substance sits on when the FDA permits compounding under enforcement discretion while it works out the longer assessment. The topical compound had a temporary safe harbour for pharmacy compounding. That safe harbour was withdrawn, pending the Wave 2 review.

Two routes, two opposite regulatory motions, one peptide, both heading to the same advisory meeting. We covered how PCAC reviews actually work in What is the PCAC. The injectable form is the editorially load-bearing one — it is the form the off-label injectable market actually sells, and its removal from Category 2 is the reason GHK-Cu is on the docket at all.

The three sentences that summarise the file

The copper-tripeptide biology is real and the mechanism volume across cells and animals is large, dominated by one research group across decades. The single published randomised human trial of GHK-Cu was on topical use after laser resurfacing and was null on every objective endpoint. The injectable form, which the off-label market sells, has no controlled human trial of any kind.

Wolverine Health is being built for the version of either route where the supervising physician has the Wave 2 outcome in front of them, the dispensing pharmacy is US-licensed, and the indication is what the FDA actually reviewed — not the cosmetic-aisle borrow the marketing relies on. Join the waitlist for a note the day the Wave 2 docket reads out.